Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.41 USD
Change Today -0.09 / -2.00%
Volume 95.8K
ICAD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

98 Spit Brook Road

Suite 100

Nashua, NH 03062

United States

Phone: 603-882-5200

Fax: 603-880-3843

iCAD, Inc. provides advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. Segments The company has two segments, Cancer Detection and Cancer Therapy. In the Cancer Detection segment, the company’s solutions include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection (CAD) systems and workflow solutions for mammography, magnetic resonance imaging (MRI), and computed tomography (CT). The Cancer Therapy segment includes the Xoft Axxent Electronic Brachytherapy system, an isotope-free cancer treatment platform technology. Products and Product Development Electronic Brachytherapy (eBx) Products Bx Treatment for Breast Cancer Axxent eBx The portable Axxent eBx system uses isotope-free miniaturized X-ray tube technology to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. The Axxent eBx system is the U.S. Food and Drug Administration (FDA)-cleared for the treatment of early stage breast cancer, endometrial cancer and non-melanoma skin cancer, as well as for the treatment of other cancers or conditions where radiation therapy is indicated, including intraoperative radiation therapy (IORT). The company offers FDA-cleared applicators utilized with the Axxent eBx system, including breast applicators for IORT and accelerated partial breast irradiation (APBI) in the treatment of breast cancer, vaginal applicators for the treatment of endometrial cancer, cervical applicators for the treatment of cervical cancer and skin applicators for the treatment of non-melanoma skin cancers. The single-use breast IORT and APBI applicators are offered in various sizes based on clinical need. The endometrial, cervical, and skin applicators are reusable and are manufactured in various sizes based on the anatomical requirements of the patient or the size of the lesion. The company also provides the 50kV isotope-free energy source, a service warranty program, and various accessories, such as the Axxent eBx Rigid Shield for internal IORT shielding. The 50kV energy source is sold either as an annual contract customized to individual customer volume/usage requirements or on a single unit basis. Customers of the Xoft eBx system include university research and community hospitals, private and governmental institutions, doctors’ offices, cancer care clinics, and veterinary facilities in the United States, Europe, and Asia; and strategic partnerships with radiation oncology service providers that enable the supervised delivery of the technology in dermatology offices. Digital and MRI CAD Products Advanced Image Analysis and Workflow Solutions in Breast Imaging (Mammography) The company develops and markets a range of CAD solutions for digital mammography systems. Its SecondLook systems are based on patented algorithms that analyze the data, automatically identifying and marking suspicious regions in the images. The system provides the radiologist with a ‘second look’, which helps the radiologist detect actionable missed cancers earlier than screening mammography alone. SecondLook detects and identifies suspicious masses and micro-calcifications utilizing image processing, pattern recognition, and artificial intelligence techniques. The company offers its next generation SecondLook Digital CAD, SecondLook Premier in Europe. SecondLook Premier is developed to provide breast imagers with the advanced and customizable digital mammography CAD system providing improved cancer detection through increased sensitivity, reduced false positives, and clinical decision support tools. Its CAD metrics provide automated measurements of mammographic characteristics for every case and each CAD detection and CAD iNSIGHT provides the rationale for each CAD detection. The company offers its next generation of mammography CAD products, PowerLook Advanced Mammography Platform (AMP). The technology expands on its SecondLook platform and is the CAD platform f

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICAD:US $4.41 USD -0.09

ICAD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr60.05 SEK -1.20
Hologic Inc $35.77 USD +0.48
Merge Healthcare Inc $4.56 USD -0.06
View Industry Companies
 

Industry Analysis

ICAD

Industry Average

Valuation ICAD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 1.1x
Price/Cash Flow 45.3x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICAD INC, please visit www.icadmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.